Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy

摘要: BACKGROUND: The use of anthracycline chemotherapy is limited by the occurrence cardiotoxicity. In an effort to prevent this cardiotoxicity, different dosage schedules (i.e. peak doses and infusion durations) have been studied. OBJECTIVES: primary objective was determine cardiotoxicity with in cancer patients. SEARCH STRATEGY: We searched databases Cochrane Register Controlled Trials (CENTRAL), (The Library, Issue 2, 2004), MEDLINE (1966 June 2004) EMBASE (1980 2004). addition, we reference lists relevant articles, conference proceedings ongoing trials databases. SELECTION CRITERIA: Randomised controlled (RCTs) which were compared patients (children adults). DATA COLLECTION AND ANALYSIS: Two authors independently performed study selection, quality assessment data-extraction including adverse effects. MAIN RESULTS: identified six RCTs varying addressing durations (625 patients). meta-analysis showed a statistically significant lower rate clinical heart failure duration 6 hours or longer as shorter duration, i.e. maximal 1 hour (RR = 0.27; 95% confidence interval (CI) 0.09 0.81; 5 studies; 557 individual studies also seemed reduce risk subclinical cardiac damage. No difference response found 0.83; CI 0.45 1.54; 2 292 overall survival (HR 1,42; 0.61 3.30; 322 patients), but there unexplained heterogeneity (I(2)=75%). conclusions can be made regarding It should emphasised that majority included these adults solid tumours. Children leukaemia could not meta-analyses, they descriptive results non-pooled studies. same cumulative dose both treatment groups identified. AUTHORS' CONCLUSIONS: An reduces failure, it seems There no evidence suggests between groups. Since only small amount data for children because obtained cannot extrapolated children, evaluated further children. For high available therefore, definitive about treated